Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$3.72 USD
+0.04 (0.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Akebia Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
AKBA 3.72 +0.04(0.95%)
Will AKBA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Other News for AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | AKBA Stock News
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business ...
Core CPI In Focus With JPMorgan, Goldman, Netflix Set To Report Earnings
Catalyst Watch: Bank earnings rush, OPEC report, Tesla EVs get Grok, and Superman at the box office